ARTICLE | Clinical News

Indivior submits NDA for RBP-7000 to treat schizophrenia

November 30, 2017 11:18 PM UTC

In September, Indivior plc (LSE:INDV) submitted an NDA to FDA for RBP-7000 to treat schizophrenia. The product is a once-monthly sustained-release formulation of risperidone using the Atrigel deliver...

BCIQ Company Profiles

Indivior plc